At Intellipharmaceutics, we are engaged in the research, development and commercialization of pharmaceutical products, both novel and generic, with a particular emphasis in the controlled-release & opioid abuse deterrence space. Intellipharmaceutics also operates a contract analytical services lab in Toronto that provides Methods Development, Validation & Transfer, Quality Control Testing, Stability Testing and Category 1 Abuse Deterrent Studies. Intellipharmaceutics International is currently trading on the OTCQB and TSX (OTCQB: IPCIF; TSX: IPCI).